Alnylam Pharma

Q2 FY2026 EarningsQ2 FY2026 results missed revenue and margin consensus despite strong 74% YoY product sales growth. Revenue of $1,290.9M missed the $1,320.3M expectation, while the gross margin of 74.6% fell short of the 76.5% target due to rising royalties. Management notably lowered full-year TTR product revenue guidance to $4.2B–$4.5B (from $4.4B–$4.7B), citing normalized demand in the ATTR-CM second-line market after satisfying initial pent-up demand.